BRIEF—New Kremezin formula to launch in Japan imminently

Japanese drug major Mitsubishi Tanabe Pharma Corporation (TYO: 4508) has announced that it will launch Kremezin Tablets 500mg (spherical cabonaceouse adsorbent), a new formula of the chronic renal failure drug, on Tuesday, January 16.

The new formulation is designed to quickly disintegrate with water in the mouth and is promised to improve the user experience and therefore medication adherence, MTPC says.

Kureha Chemical Industries (TYO: 4023) will manufacture the tablets, while MTPC will do the sales and marketing.